Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).
Nishioka
C
C
Ikezoe
T
T
Yang
J
J
Yokoyama
A
A
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002117:Calcitriol / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D004357:Drug Synergism; D007211:Indoles / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000187:drug effects / Q000473:pathology; D011758:Pyrroles / Q000494:pharmacology*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D000077210:Sunitinib; D014815:Vitamins / Q000494:pharmacology*
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D014815:Vitamins; D020794:Receptor Protein-Tyrosine Kinases; D002117:Calcitriol; D000077210:Sunitinib